Aaron Wealth Advisors LLC Has $466,000 Holdings in Edwards Lifesciences Co. (NYSE:EW)

Aaron Wealth Advisors LLC increased its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 52.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,288 shares of the medical research company’s stock after acquiring an additional 2,155 shares during the quarter. Aaron Wealth Advisors LLC’s holdings in Edwards Lifesciences were worth $466,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. FSA Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences during the 3rd quarter worth $30,000. Prospera Private Wealth LLC bought a new stake in Edwards Lifesciences during the third quarter worth about $32,000. Avior Wealth Management LLC grew its stake in Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after buying an additional 308 shares in the last quarter. Peoples Bank KS bought a new position in Edwards Lifesciences in the 3rd quarter valued at about $40,000. Finally, JFS Wealth Advisors LLC raised its position in shares of Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after buying an additional 166 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on EW. Wolfe Research lowered shares of Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price target on the stock. in a research report on Thursday. Morgan Stanley reaffirmed an “equal weight” rating and issued a $70.00 target price on shares of Edwards Lifesciences in a report on Friday, October 11th. Citigroup boosted their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. The Goldman Sachs Group raised their price objective on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. Finally, Robert W. Baird lowered their target price on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $78.48.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of the firm’s stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the sale, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,077,593.52. This trade represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 33,000 shares of company stock valued at $2,195,180 over the last 90 days. Company insiders own 1.27% of the company’s stock.

Edwards Lifesciences Stock Down 0.1 %

Edwards Lifesciences stock opened at $69.77 on Monday. The firm has a 50 day moving average price of $72.06 and a two-hundred day moving average price of $71.32. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The firm has a market cap of $41.15 billion, a price-to-earnings ratio of 10.07, a PEG ratio of 3.77 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same quarter in the previous year, the business earned $0.59 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 8.9% on a year-over-year basis. Equities analysts predict that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.